Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 225.43 |
| Open | 224.52 |
| Bid | 213.29 x 100 |
| Ask | 236.01 x 100 |
| Day's Range | 224.26 - 229.00 |
| 52 Week Range | 189.44 - 319.76 |
| Volume | |
| Avg. Volume | 1,200,520 |
| Market Cap | 32.902B |
| Beta (5Y Monthly) | -0.02 |
| PE Ratio (TTM) | 28.25 |
| EPS (TTM) | 8.00 |
| Earnings Date | Jul 23, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 283.81 |
Yahoo FinanceFDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
An FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
Investor's Business DailyEli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
Eli Lilly stock inched ahead Monday as a panel of advisors to the FDA gathered to discuss its experimental Alzheimer's treatment, donanemab.
ZacksBiogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
© 2024 Yahoo. All rights reserved.